Abcellera Biologics Inc (ABCL) Event June 21, 2022, 16:28 UTC (50% Neutral) ABCELLERA BIOLOGICS INC. (ABCL) Announces Regulatory Update Full text
Register to leave comments News bot Oct. 2, 2025, 8:34 a.m. 📋 ABCELLERA BIOLOGICS INC. (ABCL) - Regulatory Update Filing Date: 2022-06-21 Accepted: 2022-06-21 12:28:55 Event Type: Regulatory Update Event Details: Abcellera Biologics Inc (ABCL) Announces Regulatory Update Abcellera Biologics Inc (ABCL) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development: 🔬 Clinical Development Pipeline (ABCELLERA BIOLOGICS INC.): Product Type Development Stage Therapeutic Area Source Placebo BIOLOGICAL Phase PHASE1 Vasomotor Symptoms Associated With Menopause ClinicalTrials.gov ABCL635 BIOLOGICAL Phase PHASE1 Vasomotor Symptoms Associated With Menopause ClinicalTrials.gov QBKPN SSI BIOLOGICAL Phase PHASE2 Non-Small Cell Lung Cancer ClinicalTrials.gov QBECO DRUG Phase PHASE1 Crohn's Disease ClinicalTrials.gov Placebo (Normal Saline 0.9%) BIOLOGICAL Phase EARLY_PHASE1 Healthy Volunteers ClinicalTrials.gov ABCL575 BIOLOGICAL Phase EARLY_PHASE1 Healthy Volunteers ClinicalTrials.gov Lenalidomide DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov Romidepsin DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov 💼 Business Developments: Partnership: Not availableAcquisition: Not availableLicensing: Not availableRegulatory ApprovalExecutive Changes: Not available Structured Data: Company Name: Abcellera Biologics IncCIK: 0001703057Ticker Symbol: ABCLPeriod End Date: 2022-06-15Document Type: 8-K
📋 ABCELLERA BIOLOGICS INC. (ABCL) - Regulatory Update
Filing Date: 2022-06-21
Accepted: 2022-06-21 12:28:55
Event Type: Regulatory Update
Event Details:
🔬 Clinical Development Pipeline (ABCELLERA BIOLOGICS INC.):
💼 Business Developments:
Structured Data: